Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
| 11.63 | |
| 11.57 | |
| - | |
| 11.64 | |
| 11.29 | |
| 5.71-16.99 | |
| 876 M | |
| 76 414 K | |
| 15 967 K | |
| -0.54 | |
| 0.321 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Liquidia Corporation (NASDAQ:LQDA) Q4 2023 Earnings Call Transcript March 13, 2024 Liquidia Corporation misses on earnings expectations. Reported EPS is $-0.42 EPS, expectations were $-0.23. LQDA isn...
Wednesday, United Therapeutics Corporation (NASDAQ:UTHR) initiated legal action against the FDA, claiming that the FDA wrongly allowed Liquidia Corporation (NASDAQ:LQDA) to deviate from established r...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
